Question

帮我翻译成英语（不要拿到“在线翻译软件”翻译那里的语法顺序不正确）

目的：应用缬沙坦联合参芪扶正液对糖尿病大鼠模型进行干预，观察其对血糖、血脂、肾功、蛋白尿、血浆AngII水平、肾病理改变及肾组织中TGF-β受体和FNmRNA表达的影响，探讨两药在对糖尿病大鼠肾脏保护方面是否存在协同效应。方法：55只Wistar大鼠，其中47只禁食12～16小时，自由饮水，以50mg/kg的剂量一次性腹腔注射2%链脲佐菌素（streptozotocin STZ）， 72h后内眦采血测空腹血糖≥16.7mmol/L者为糖尿病大鼠，纳入实验，造模不成功者剔除。另外8只大鼠列为正常组，注射相当体积的柠檬酸缓冲液。糖尿病大鼠随机分为3组：模型组，参芪扶正液组、缬沙坦组和联合组 (缬沙坦与参芪扶正液联合治疗组)。糖尿病（Diabetes Mellitus, DM）模型建立后即刻开始治疗, 按大鼠与人等效剂量折算方法每天定时灌胃给予缬沙坦10 mg/kg/d和参芪扶正注射液200mg/kg/d灌胃,联合组10 mg/kg/d/+200mg/kg/d，对照组和模型组给予等量0.9%NS。第8周时处死大鼠，观察血糖、血脂、肾功能、蛋白尿、肾脏病理改变、血浆Ang II水平、肾组织TGF-β受体 和FNmRNA表达量。结果：与正常组相比,模型组及各给药组大鼠血糖、血脂、肾功、尿蛋白、血浆AngII均显著上升（P<0.05或P<0.01）；肾小球平均面积、毛细血管基底膜平均厚度均显著扩大（P<0.05）；肾组织中TGF-β受体和FNmRNA表达显著上调（P<0.05）。缬沙坦、 参芪扶正液干预后, 参芪扶正液能降低高血糖 （P<0.01），提高HDL水平，降低CHO、 TG水平（P<0.05或P<0.01），但缬沙坦对高血糖状态、血脂代谢紊乱影响不大（P > 0.05）；参芪扶正液在减轻肾脏肥大、抑制肾脏TβRI、TβRII和FNmRNA的表达方面作用强于缬沙坦（P<0.05）； 缬沙坦降低Ang II水平方面强于参芪扶正液（P<0.05）；联合治疗组可进一步降低尿蛋白、肾脏肥大指数、肾小球平均面积，减轻GBM增厚（P<0.05）。结论：1. 参芪扶正液能够降低血糖、血脂，改善肾功能，降低蛋白尿、Ang II水平，抑制肾脏TβRI、TβRII和FNmRNA的表达。2.缬沙坦对高血糖、高血脂没有明显的作用，但也能改善一般状况及肾功能，降低蛋白尿，Ang II水平。3.参芪扶正液和缬沙坦具有协同效应：参芪扶正液在减轻肾脏肥大、抑制肾脏TβRI、TβRII和FNmRNA的表达方面作用强于缬沙坦；缬沙坦降低Ang II水平方面强于参芪扶正液；联合治疗组可进一步降低尿蛋白、肾脏肥大指数、肾小球平均面积，减轻GBM增厚。
关键词：糖尿病肾病 缬沙坦 参芪扶正液 转移生长因子β系统（TβRI、TβRII）和纤维连接蛋白（FN） Ang II 联合治疗

Answer 1

Objective: the application of losartan CanQi joint on centralizer diabetic rats model, the intervention of blood glucose, blood fat, renal function, albuminuria, plasma AngII level, kidney pathological changes and kidney tissues beta receptors and TGF - FNmRNA expression, this paper discusses the influence of the two drugs in diabetic rats renal protection exists synergy effect. Methods: 55 Wistar rats, which only 47 fasting 12-16 hours, free water/kg of 50mg, one-time dose intraperitoneal injection of 2% (urea chain with bacteria STZ streptozotocin 72h), angular measuring blood after fasting glucose mmol/L experiment.it 16.7 for diabetic rats, into the experiment, the no winners. Eight others as normal rats, injection of citric acid buffer is volume. Diabetic rats were randomly divided into three groups: model group, CanQi centralizer liquid, losartan and joint group (losartan and CanQi centralizer combination therapy group). Liquid Diabetes Mellitus (DM) and Diabetes after the establishment of the model, and begin treatment by rats and equivalent conversion dose lavage gives every timing method of losartan 10 mg/kg/d and CanQi centralizer injection 200mg/kg/d, joint lavage groups of 10 mg/kg/d / + 200mg/kg/d group, and group given equal 0.9% NS model. Article 8 weeks, when executed rats blood glucose, blood fat, kidney observation, albuminuria, kidney pathological changes, plasma levels, renal tissue Ang II TGF beta receptors and FNmRNA expression -. Results: compared with the normal group, and each drug model of rats blood glucose, blood group, renal function, urinary protein, plasma AngII significantly (P < 0.05) or P < 0.01), Glomerular basement membrane average area, capillary average thickness were significantly expand (P < 0.05). Renal tissues beta receptors and FNmRNA TGF - express significant increase (P < 0.05). Losartan, CanQi centralizer after intervention, CanQi centralizer liquid fluid can reduce high blood glucose (P < 0.01), increase HDL levels, reduce CHO, TG level (P < 0.05 or P < 0.01), but losartan to high status, lipid metabolism disorders affect (P > 0.05) is, CanQi lifter in liquid, kidney kidney hypertrophy, t. t. beta RI RII beta FNmRNA and expressed in the role than losartan (P < 0.05). Losartan Ang lower level II CanQi than lifter fluid (P < 0.05). Combined treatment group can further reduce urine protein, renal glomerulus index, the average area hypertrophy, alleviate these GBM thickening (P < 0.05). Conclusion: 1. To reduce blood sugar CanQi centralizer and lipids, improve renal function, reduce albuminuria, Ang II levels, kidney, T T beta RI RII beta FNmRNA and express. 2. Of hyperglycemia valerian, hyperlipidemia no obvious effect, but also can improve the general situation and kidney function, reduce albuminuria, Ang II levels. 3 CanQi centralizer and losartan synergistic effects: CanQi centralizer in liquid, kidney T kidney hypertrophy, RI beta RII beta FNmRNA and expressed in the role than losartan, Losartan Ang lower level II CanQi centralizer than liquid, Combined treatment group can further reduce urine protein, renal glomerulus index, the average area hypertrophy, alleviate these GBM thickening.
Keywords: diabetic nephropathy losartan CanQi centralizer liquid transfer growth factor beta system (T beta RI, T beta RII) and fibronectin (12.7mm FN) Ang II combination therapy

Answer 2

额滴个娘喔……本来想帮的，还是算了，省得误人子弟……

Answer 3

这需要非常非常专业的人士才能翻译，太专业了。

Answer 4

靠，着要怎么翻，就算发出来了，你也不知道对不对~呵呵~(*^__^*)...